AJOVY HAS A LONG HALF-LIFE¹

AJOVY^® (fremanezumab-vfrm)¹	Aimovig^® (erenumab-aooe)²	Emgality^® (galcanezumab-gnlm)³
31 Days	28 Days	27 Days

This information should not be construed to imply any difference in safety, efficacy, or other clinical outcome. View the safety profile of AJOVY.

AJOVY^® (fremanezumab-vfrm)¹	31 Days
Aimovig^® (erenumab-aooe)²	28 days
Emgality^® (galcanezumab-gnlm)³	27 days

This information should not be construed to imply any difference in safety, efficacy, or other clinical outcome. View the safety profile of AJOVY.

Pharmacokinetic profile of AJOVY^4,5

PHASE 1 STUDY ASSESSING PHARMACOKINETIC PARAMETERS⁴*

Graph of PK data showing AJOVY monthly dose at month 1 and AJOVY quarterly dose at month 3 having similar serum concentrations.

225 mg of AJOVY

675 mg of AJOVY

AJOVY was evaluated in a phase 1 study to assess pharmacokinetic parameters for both monthly and quarterly dosing in healthy volunteers.⁴

Serum concentrations of AJOVY were sustained throughout both the monthly and quarterly dosing periods.⁵

Once steady state is reached, the washout period^† for AJOVY is similar for monthly and quarterly dosing (~5-6 half-lives)⁶

^†Washout period defined as time until plasma concentrations of AJOVY are below a clinically relevant concentration and thus considered eliminated.

Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection site reactions.

AJOVY is indicated for the preventive treatment of migraine in adults.

Please see full Prescribing Information for AJOVY.

*A phase 1 study evaluated the pharmacokinetic profile, safety, tolerability, and immunogenicity of the doses of AJOVY tested in the phase 2 and 3 trials (225 mg and 675 mg) following single administration in healthy subjects. Healthy subjects in this phase 1 study who were given a 225 mg dose had a mean concentration of 22.1 μg/mL at day 29 and those given 675 mg had a mean concentration of 24.1 μg/mL at day 85. These time points approximate the end of the monthly and quarterly dosing ranges, respectively.^4,5

References: 1. AJOVY® (fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc. 2. Aimovig® (erenumab-aooe) injection. Prescribing Information. Thousand Oaks, CA: Amgen Inc. 3. Emgality® (galcanezumab-gnlm) injection. Prescribing Information. Indianapolis, IN. Lilly USA, LLC. 4. Cohen Barak O, Weiss S, Rasamoelisolo M, et al. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia. 2018;38(13):1960-1971. 5. Data on file. Parsippany, NJ: Teva Pharmaceuticals USA, Inc. 6. Hallare J, Gerriets V. Half Life. In: StatPearls [Online]. StatPearls Publishing; January 2020. Updated October 6, 2020. https://www.ncbi.nlm.nih.gov/books/NBK554498/

AJOVY HAS A LONG HALF-LIFE1

Pharmacokinetic profile of AJOVY4,5

PHASE 1 STUDY ASSESSING PHARMACOKINETIC PARAMETERS4*

AJOVY HAS A LONG HALF-LIFE¹

Pharmacokinetic profile of AJOVY^4,5

PHASE 1 STUDY ASSESSING PHARMACOKINETIC PARAMETERS⁴*